In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a novel class of antidiabetic and anti-obesity agents, have gained widespread recognition for their safety, efficacy, and metabolic benefits in managing T2DM and obesity. This evidence concerns the gene GLP1R and obesity disorder.